Advanced Aesthetic Technologies Announces Appointment of Doug Abel As Chief Executive and President

BROOKLINE, Mass.–(BUSINESS WIRE)–Advanced Aesthetic Technologies, Inc. (ATT), a leader in aesthetic gel
implant technology, today announced the appointment of Doug Abel as
Chief Executive Officer and President, effective immediately. Mr. Abel
will lead the Company’s global initiative and advance the development of
its gel technology for the aesthetic and healthcare markets.

Richard Burtt, Chairman of Advanced Aesthetic Technologies commented,
“We are thrilled to announce the appointment of Doug Abel as Chief
Executive and President. Doug brings deep aesthetic technology industry
expertise and perspective gained through over 25 years of medical device
and specialty pharma experience including senior roles at Sinclair,
Allergan, and Biogen. Doug’s successful career of scaling aesthetic
businesses and developing and launching new products is ideally suited
for AAT’s all-natural gel technology.”

Mr. Abel noted, “I am inspired and excited by the opportunities and
tremendous potential of this unique and natural gel technology. The
Algeness® gel technology offers a compelling value
proposition built on its all-natural composition and true fully
biodegradable performance and offers a full product range in aesthetic
medicine. I am excited and energized to join the Advanced Aesthetic
Technology team and lead the continued development of the Algeness®
gel technology.”

About Doug Abel

Mr. Abel comes to AAT, Inc after leading the North American operations
of Sinclair Pharma since 2015. Doug was responsible for the launch of
Sinclair’s aesthetic products in the US and pipeline development efforts
to bring an expanded portfolio to the US and Canada. Previously Doug
held senior positions at Allergan and Biogen along with several early
stage device businesses. During his 25 year experience in aesthetic
medicine, Doug has been a member of the Allergan leadership team that
built and executed the re-entry into dermatology; both medical
dermatology and topical aesthetics/skincare and served as the global
lead for BOTOX® aesthetic and hyperhidrosis development and
commercial launch initiatives. As VP of Dermatology at Biogen, Doug
built and led the team that launched the first Biologic approved for
psoriasis. Also, as General Manager of Onset Dermatologics, he built out
the commercial team, led the development of multiple new products, and
grew revenue over 6 fold.

Doug holds a BA in Chemistry from Lafayette College and an MBA from
Temple University.

About the Aesthetic Industry

According to Market Research Future, the global dermal fillers market is
expected to grow at a compound annual growth rate of 12.5% over the next
five years and is expected to reach $10 billion by 2023. The major
factors driving the growth of this market are increased demand by both
practitioners and consumers towards the use of minimally invasive and
non-invasive procedures.

Worldwide, more than 7-8 million filler procedures are performed
annually by plastic surgeons, dermatologists and other practitioners. In
the US alone, plastic surgeons performed nearly 3.5 million Hyaluronic
Acid filler procedures in 2016, representing over 25% of the
non-surgical procedures performed by these surgeons.(1)

About Algeness®

Algeness is the all-natural, biodegradable, biocompatible agarose-based
gel implant, free of all synthetic or cross-linking chemicals; and
proven through multiple clinical studies in Europe. The uniqueness of
Algeness dermal fillers is its abilities to add immediate volume in the
facial area with excellent persistence without the added cross-linked
chemicals required by all Hyaluronic Acid fillers. Algeness is
formulated in several injectable concentrations to match specific
cosmetic improvements of the lips, fine lines, and the folds around the
mouth and for shaping and volumizing the cheeks, jawline and other
areas. With the CE Mark certification, Algeness is available in 33
countries in Europe, South America, Asia, and the Middle East.

(1) 2016 International Study of Cosmetic Surgery,
International Society of Aesthetic Plastic Surgery
Algeness®
and Master Your Results® are registered trademarks of AAT,
Inc. and its subsidiary Algeness-Europe Ltd, Ireland.

Contacts

Richard Burtt, Chairman
Advanced Aesthetic Technologies, Inc.
Brookline,
MA USA
+1-617-901-6637
[email protected]
www.algeness.com

error: Content is protected !!